<DOC>
	<DOCNO>NCT00002371</DOCNO>
	<brief_summary>To compare magnitude durability reduction plasma HIV RNA two treatment group first 12 week treatment . To determine safety two treatment group .</brief_summary>
	<brief_title>The Safety Effectiveness Lamivudine Plus Stavudine Zidovudine HIV-Infected Patients Who Have Taken Zidovudine</brief_title>
	<detailed_description>Patients randomize either Stavudine ( d4T ) + Lamivudine ( 3TC ) + Zidovudine placebo Zidovudine ( ZDV ) + Lamivudine + Stavudine placebo . Patients whose plasma HIV RNA level remain &gt; = 500 copies/ml 8 week blind double combination therapy indinavir add treatment regimen week 12 visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : At least six month prior cumulative ZDV therapy . Qualifying plasma HIV RNA count &gt; = 4 log10 copies/ml obtain within 2 week randomization . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Presence newly diagnose AIDS define opportunistic infection require acute therapy time enrollment . Intractable diarrhea ( &gt; = 6 loose stools/day &gt; = 7 consecutive day ) . Signs symptoms bilateral peripheral neuropathy &gt; = grade 2 time screen . Inability tolerate oral medication . Any clinical condition opinion investigator , would make patient unsuitable study unable comply dose requirement . Concurrent Medication : Excluded : Therapy agent systemic myelosuppressive , neurotoxic pancreatotoxic , hepatotoxic cytotoxic potential . Therapy rifampin , rifabutin , terfenadine , astemizole , cisapride , triazolam , midazolam ketoconazole time indinavir therapy . Patients follow prior condition symptom exclude : History acute chronic pancreatitis . Prior history bilateral peripheral neuropathy . Intractable diarrhea ( &gt; = 6 loose stools/day &gt; = 7 consecutive day ) within 30 day prior study entry . Prior Medication : Excluded : Any prior antiretroviral therapy except ddI , ddC , 3TC ZDV ( ZDV , specify inclusion criterion ) . Previous therapy agent significant systemic myelosuppressive , neurotoxic pancreatotoxic , hepatotoxic cytotoxic potential within 3 month study start . Therapy rifampin , rifabutin , terfenadine , astemizole , cisapride , triazolam , midazolam ketoconazole within 2 week prior start indinavir . Any prior therapy , opinion investigator , would make patient unsuitable study unable comply dose regimen . Risk Behavior : Excluded : Active alcohol abuse , sufficient investigator 's opinion , prevent compliance study therapy increase risk develop pancreatitis . Required : At least 6 month prior cumulative ZDV therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>